4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Ma'ema'e Waena >99.0% (HPLC)

ʻO ka wehewehe pōkole:

Inoa Kemika: 4-Amino-3-Chlorophenol

CAS: 17609-80-2

Maʻemaʻe: >99.0% (HPLC)

Nānā: Pada Paʻa Paʻa

Kūwaena o Lenvatinib Mesylate CAS 857890-39-2

Hoʻokaʻaʻike: Kauka Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Na Waiwai Kemika:

Inoa Kimia 4-Amino-3-Chlorophenol
Nā huaʻōlelo like 3-Chloro-4-Aminophenol;Lenvaint-G
Helu CAS 17609-80-2
Helu CAT RF-PI1968
Kūlana Kūʻai Ma ka waihona, hoʻonui ʻia a hiki i nā tona
ʻĀpana Molekala C6H6ClNO
Kaumaha Molecular 143.57
ʻO ka mānoanoa 1.406±0.060 g/cm3
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Pada Paʻa Palaka
1 H NMR Spectrum Kūlike me ka hoʻolālā
ʻIkepili-HPLC ʻO ka manawa paʻa e like me ka maʻamau
Maʻemaʻe / Kaʻina Hanana >99.0% (HPLC)
Lae hehee 138.0~141.0 ℃
Nalo ma ka maloo <1.00%
Koena ma ka Ignition <0.30%
Huina paumaele <1.00%
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana Waena o Lenvatinib Mesylate (CAS: 857890-39-2)

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai

Pono:

1

FAQ:

Noi:

ʻO 4-Amino-3-Chlorophenol (CAS: 17609-80-2) he mea koʻikoʻi ka lāʻau lapaʻau koʻikoʻi, i hoʻohana nui ʻia i ka hoʻolālā a me ka synthesis o nā anti-tumor, nā maʻi cardiovascular, nā maʻi maʻi neurological.ʻO 4-Amino-3-Chlorophenol kahi mea koʻikoʻi waena i ka hoʻomākaukau ʻana o Lenvatinib Mesylate (CAS: 857890-39-2).Hoʻomohala ʻia e Eisai Inc., ʻo lenvatinib mesylate he mea hoʻokae endothelial growth factor receptor (VEGF) i loaʻa ka hana e kūʻē i nā subtypes VEGF 1, 2, a me 3 a ua ʻae ʻia e ka FDA ma 2015 no ka mālama ʻana i ka maʻi maʻi thyroid like ʻole. hou, metastatic, a holomua paha a ʻaʻole i pane i ka lāʻau iodine radioactive.I Mei 2016, ua ʻae ka FDA i ka lāʻau lapaʻau ma ke ʻano he hui hui me everolimus no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma.No ka mea, ua manaʻo ʻia ʻo VEGF (a me ka fibroblast growth factor receptors, i kapa ʻia ʻo FGFRs) i ke kuleana i nā ala hōʻailona cardiovascular, ua manaʻo ʻia ʻo VEGF2R a me FGFR inhibition nā mea hana ma hope o ka hopena mua o ka lenvatinib mesylate, ʻo ia ka hypertension.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou